

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 31, 2015

NewLink Genetics Corporation
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-35342
(Commission
File Number)

42-1491350
(IRS Employer
Identification No.)

2503 South Loop Drive
Ames, IA
(Address of principal executive offices)

50010
(Zip Code)

Registrant's telephone number, including area code: **(515) 296-5555**

Not applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 8 - Other Events

Item 8.01. Other Events.

On July 31, 2015, NewLink Genetics Corporation, a Delaware corporation (the "Company"), issued a press release reporting that the international partnership studying the VSV-ZEBOV (Ebola) vaccine candidate in Guinea has released interim data suggesting that it is effective against Ebola in a large trial.

The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Section 9 - Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press Release, dated July 31, 2015, entitled "Vaccine Candidate Potentially Effective Against Ebola in Large Trial in Guinea"

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 31, 2015

NewLink Genetics Corporation

By: /s/ John B. Henneman III
John B. Henneman III
Its: Chief Financial Officer

INDEX TO EXHIBITS

Exhibit Number	Description
99.1	Press Release, dated July 31, 2015, entitled "Vaccine Candidate Potentially Effective Against Ebola in Large Trial in Guinea"



FOR IMMEDIATE RELEASE

Vaccine Candidate Potentially Effective Against Ebola In Large Trial In Guinea

VSV-ZEBOV Interim Data Released

AMES, Iowa - July 31, 2015 -- NewLink Genetics Corporation (NASDAQ: NLNK) today announced that the international partnership studying the VSV-ZEBOV (Ebola) vaccine candidate in Guinea has released interim data suggesting that it is effective against Ebola in a large clinical trial. According to the announcement, the interim results suggest that the vaccine candidate demonstrates efficacy within about 10 days of administration to a person without the infection.

The VSV-ZEBOV (Ebola) vaccine candidate was originally developed by the Public Health Agency of Canada (PHAC), and was subsequently licensed to a subsidiary of NewLink Genetics. In late 2014, Merck licensed the vaccine from NewLink Genetics to apply Merck's vaccine expertise to help accelerate the development of this promising candidate. Merck is now responsible for research, development and manufacturing of the rVSV-ZEBOV vaccine.

"NewLink appreciates the tremendous support for these studies from our many collaboration partners, including Merck, the government of Canada and the U.S. Department of Health and Human Services (Centers for Disease Control, the National Institutes of Health and the Biomedical Advanced Research and Development Authority), and especially the U.S. Department of Defense, which provided funding for the development and manufacturing of the vaccine, the World Health Organization, and the many other organizations that stepped forward in the crisis to support the development of this vaccine and the clinical studies in Africa," said Dr. Charles Link, Chairman, Chief Executive Officer, and Chief Scientific Officer of NewLink Genetics. "We hope that the interim data published today contribute to the successful registration of our vaccine candidate, which we believe can play an important part in diminishing the threat of Ebola."

Because of the Ebola crisis, a large team was assembled which included scientists, physicians, epidemiologists and other experts from the World Health Organization (WHO), Norway, Canada, Guinea, Doctors without Borders, the Universities of Florida, Maryland and Bern, and the London School of Hygiene & Tropical Medicine. Funding for the trial came from the Wellcome Trust, Norway, Canada, WHO, and Doctors without Borders. NewLink Genetics and Merck (known as MSD outside the United States and Canada), one of the world's leading vaccine and pharmaceutical companies, provided the vaccine. Scientists from NewLink Genetics and Merck also gave detailed technical support on the vaccine and its administration to field trial staff.

The international partnership's statement can be found in a joint announcement of the Wellcome Trust, the London School of Hygiene & Tropical Medicine, the Norwegian Institute of Public Health, Doctors Without Borders, Merck, the Public Health Agency of Canada, the Lancet, and Ministère de la Santé et de l'Hygiène Publique de Guinée.

About NewLink Genetics Corporation

NewLink Genetics is a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve treatment options for patients with cancer. NewLink Genetics' portfolio includes biologic and small-molecule immunotherapy product candidates intended to treat a wide range of oncology indications. NewLink Genetics' product candidates are designed to harness multiple components of the immune system to combat cancer without significant incremental toxicity, either as a monotherapy or in combination with other treatment regimens.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements of NewLink that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release are forward-looking statements, within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "target," "potential," "will," "could," "should," "seek" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about results of its clinical trials for product candidates; its timing of release of data from ongoing clinical studies; its plans related to moving additional indications into clinical development; and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that NewLink makes due to a number of important factors, including those risks discussed in "Risk Factors" and elsewhere in NewLink Genetics' Annual Report on Form 10-K for the year ended December 31, 2014 and other reports filed with the U.S. Securities and Exchange Commission (SEC). The forward-looking statements in this press release represent NewLink's views as of the date of this press release. NewLink anticipates that subsequent events and developments will cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing NewLink Genetics' views as of any date subsequent to the date of this press release.

Corporate Contact:

Jack Henneman

Chief Financial Officer, NewLink Genetics

515-598-2561

Investor@linkp.com

Investors:

Donna LaVoie

LaVoieHealthScience

617-374-8800, ext. 107

dlavoie@lavoiehealthscience.com

Media:

David Connolly

LaVoieHealthScience

617-374-8800, ext. 108

dconnolly@lavoiehealthscience.com